Tech Company Financing Transactions
Promentis Pharmaceuticals Funding Round
Promentis Pharmaceuticals closed a $8.8 million funding round on 10/6/2016. Investors included private investors.
Transaction Overview
Company Name
Announced On
10/6/2016
Transaction Type
Venture Equity
Amount
$8,787,399
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 8 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
826 N. Plankinton Ave. 400
Milwaukee, WI 53203
USA
Milwaukee, WI 53203
USA
Phone
Undisclosed
Website
Email Address
Overview
Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Klaus Veitinger
President
Daniel Lawton
VP - Finance
Stacy Holland
VP - R & D
Chad Beyer
VP - R & D
Michael Neary
Browse more venture capital transactions:
Prev: 10/6/2016: Reaction Commerce venture capital transaction
Next: 10/6/2016: Aspyrian Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs